Delegation of the State of Oregon
|State of Oregon
|Room San Francisco, 3rd floor
Oregon Bioscience Association (Oregon Bio)
Business Oregon is the State of Oregon’s economic development agency. Bioscience is one of Oregon’s leading Target Industries and has become an emerging, competitive segment of Oregon’s economy. Due to a recent influx of firms, and expansions, like Twist Bioscience and Genentech (a Roche Subsidiary) which together will create over 700 new jobs), Oregon’s bio community is growing faster and gaining more market share vs. many other U.S. states. With 1,480 establishments, Oregon’s Bio market produced $15.7 billion (2020) in total economic output, and nearly $1 billion (2019) in pharmaceuticals, medicine, and medical equipment.
Additional Information: As one of the fastest-growing parts of Oregon’s innovation economy, bioscience is generating exciting new research, and life-changing products, and attracting increased amounts of venture capital, and foreign direct investment. Our core functions include business retention, expansion, and recruitment; export promotion and international trade; industry research and development and entrepreneurship; small business assistance; rural community development and infrastructure financing; and support for arts and cultural organizations.
Aronora is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines for blood diseases with significant unmet medical needs. We have a talented and dedicated team of scientists and clinicians with extensive experience in pharmaceutical product development, from discovery through commercialization. Our robust pipeline of innovative product candidates targets disease-modifying pathways with unique mechanisms of action.
Additional information: Aronora’s innovations are built upon more than two decades of basic research into blood-clotting mechanisms, and our efforts have been focused on isolating the differences between good blood clots (hemostasis) and bad ones (thrombosis), with the ultimate goal to translate this fundamental knowledge into safer blood thinning and ‘clot- busting’ therapies. Aronora’s products take advantage of this new understanding to inhibit only thrombosis without affecting hemostasis, and thus our pioneering antithrombotic drugs should have limited to no bleeding side effects.
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug discovery efforts.
Additional information: An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in the early-stage development of new compounds.
- Conduct early identification of potential hit targets
- Perform drug toxicity and efficacy testing
- Identify drug repurposing for rare genetic diseases
Oregon Bioscience Association (Oregon Bio)
Oregon Bio is a member trade association that supports the regional bioscience community through networking, workforce development, educational programs, enterprise support, advocacy, and the promotion of research collaborations. We also represent the state’s biotech research institutions, industry service providers, and academic centers of learning.
Additional Information: Oregon Bio continually seeks ways to support sustainability and growth in the life science, bioscience, biotechnology, and device manufacturing sectors. Oregon Bio is an affiliate of the Biotechnology Innovation Organization. Our members are involved in cutting-edge research and development of innovative healthcare, agricultural, and environmental biotechnologies. Our corporate members range from entrepreneurial startups developing a first product to large multinationals.
Rewire Neuro provides AI-based image analysis solutions for researchers, clinicians, and OEM hardware integrations with partnering companies.
Additional Information: Rewire AI is focused on improving the speed and accuracy of biomedical image analysis, with a direct-to-researcher implementation of our cloud-based computer vision platform, as well as custom integrations of our AI platform with optical microscopy products for automated biomarker detection.
Analysis of biomedical images by histologists and pathologists still depends heavily on manual analysis methods, which are time-intensive and introduce bias and error that compromises the reliability of clinical diagnoses and research findings. AI and computer vision are revolutionizing automated image analysis and Rewire Neuro is at the forefront of making this technology intuitive and easily accessible.
Sightologist.ai is a cloud-based computer vision platform that integrates with optically-based diagnostic hardware or software, such as microscopes, plate-readers, and imaging systems, to automatically detect protein and cellular biomarkers in real-time. Sightologist AI-as-a-Service is available for partner integration to perform real-time or post-hoc image analysis while improving data accuracy by 96%, reducing analysis time by 99%, and reducing costs for our customers by at least 80%. Additionally, Rewire offers direct-to-researcher access to the Sightologist.ai platform through its own downloadable software, called Polygon AI.
UbiVac is a clinical stage biotech engaged in research and development, and manufacture, of therapeutic immune activators, vaccines, and cellular immunotherapies to combat cancer. Used in combination with other immunotherapies, UbiVac’s patented technologies have proven highly effective at improving survival and apparent cure in difficult-to-treat animal cancers.
Additional Information: UbiVac has unique and disruptive immune educating and activating vaccine technology. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer neoantigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers. Due to its unique platform vaccine technology, novel targets are being discovered that might be used for ADC, CAR-T/NK, and TCR gene therapy. UbiVac postulates that by applying machine learning, artificial intelligence, and generative adversarial networks to the analysis of the extensive monitoring data from these ongoing first-in-human trials, new insights will allow future trials to tailor treatment regimens and further improve outcomes of patients with cancer